• Anticancer Nanotechnology: Molecular Mechanism and Drug Delivery of Nanoparticulophagy (奈米自噬的分子調控機制及藥物遞送功能)
  • Anticancer Targets: Cancer targets and Overcoming Drug Resistance by nanoparticulophagy (奈米自噬的癌症標靶與克服抗藥性機制)
  • Anticancer Drugs: Developing Novel Drugs by Nanoparticulophagy for Cancer Therapy (開發新型奈米自噬藥物在癌症治療)

The Chao laboratory has contributed the roles of Survivin and EGFR in regulating tumor growth and drug resistance. We seek to translate insights in inhibiting cancer growth genes by novel compounds into improved therapies for malignant tumors. Our studies contributed nanodiamond, a carbon-based nanomaterial, on biocompatible evaluation, bio-labeling, drug delivery and biological impacts. Selective autophagy plays a pivotal role in the processing of foreign pathogens, cellular components, and damaged organelles to maintain homeostasis in human cells. Selective autophagy receptors contain an Ub-associated domain and an LC3-interacting region, which can recruit LC3-containing autophagosomes to ubiquitinated cargos into selective autophagy pathway. We found for the first time that ubiquitin-coated nanodiamonds bind to selective autophagy receptors (SQSTM1, OPTN and NDP52) for entry into the selective autophagy pathway. Our study provides novel insight that ubiquitin-coated nanoparticles bind to autophagy receptors for entry into the selective autophagy pathway, which is called nanoparticulophagy, facilitating their delivery to lysosomes. We illustrate the biological impacts and pivotal roles of autophagy receptors in transportation and drug delivery by those nanomaterials. In recent years, we focus on the investigation of selective autophagy receptors in cancers and nanodrug delivery.